Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time

Thrombosis and Haemostasis

Volumn 106, Issue 1, 2011, Pages 156-164

  Mani, Helen ^a   Hesse, Christian ^a   Stratmann, Gertrud ^a   Lindhoff Last, Edelgard ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Activated partial thromboplastin time; Antithrombin; Fibrinogen; Prothrombin time; Rivaroxaban; Thrombin time

Indexed keywords

ANTITHROMBIN; ENOXAPARIN; FIBRINOGEN; RIVAROXABAN; THROMBIN;

AGED; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; EX VIVO STUDY; FEMALE; HUMAN; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; PROTHROMBIN TIME; STEADY STATE; THROMBIN TIME; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; ANTITHROMBINS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CLINICAL PROTOCOLS; DRUG INTERACTIONS; FACTOR XA; FEMALE; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; ORTHOPEDIC PROCEDURES; POSTOPERATIVE COMPLICATIONS; THIOPHENES; TIME FACTORS; VENOUS THROMBOEMBOLISM;

EID: 79960068693     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-10-0667     Document Type: Article

References (28)

1. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (8th Edition). 2008; 133 (6 Suppl): 381S-453S.
2. Phillips KW, Ansell J. The clinical implications of new oral anticoagulants: will the potential advantages be achieved? Thromb Haemost 2010; 103: 34-39.
3. Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V. Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol 2010; 30: 376-381.
4. Laux V, Perzborn E, Heitmeier S, et al. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy? Thromb Haemost 2009; 102: 892-899.
5. Eriksson BI, Borris L, Dahl OE, et al.; ODIXa-HIP Study Investigators. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006; 4: 121-128.
6. Merli G, Spyropoulos AC, Caprini JA. Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations. Ann Surg 2009; 250: 219-228.
7. Ageno W. Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials. Expert Rev Cardiovasc Ther 2009; 7: 569-576.
8. Turpie AG, Lassen MR, Eriksson BI, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011; 105: 444-453.
9. Xarelto® Summary of Product Characteristics. 2009. http://emc.medicines.org.uk/medicine/21265/SPC/Xarelto 10 mg film-coated tablets.
10. Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 412-421.
11. Mueck W, Eriksson BI, Bauer KA, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor-in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 2008; 47: 203-216.
12. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005; 3: 514-521.
13. Mueck W, Borris LC, Dahl OE, et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008; 100: 453-461.
14. Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61: 873-880.
15. Samama MM, Martinoli JL, LeFlem L, et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 2010; 103: 815-825.
16. Jiang J, Hu Y, Zhang J, et al. Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct factor Xa inhibitor - in elderly Chinese subjects. Thromb Haemost 2010; 103: 234-241.
17. Graff J, von Hentig N, Misselwitz F, et al. Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol 2007; 47: 1398-1407.
18. Merriman E, Kaplan Z, Butler J, et al. Rivaroxaban and false positive lupus anticoagulant testing. Thromb Haemost 2011; 105: 385-386.
19. Ufer M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost 2010; 103: 572-585.
20. Lindhoff-Last E, Samama MM, Ortel TL, et al. Assays for Measuring Rivaroxaban: Their Suitability and Limitations. Ther Drug Monit 2010; 32: 673-679.
21. Hillarp A, Baghaei F, Blixter IF, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011; 9: 133-139.
22. Hawkey CJ, Stirling Y, Chakrabarti R, et al. Haemostatic changes following surgery. Thromb Res 1983; 32: 223-227.
23. Lowe GD, Rumley A, Mackie IJ. Plasma fibrinogen. Ann Clin Biochem 2004; 41: 430-440.
24. Mismetti P, Laporte S. New oral antithrombotics: a need for laboratory monitoring. J Thromb Haemost 2010; 8: 621-626.
25. Samama MM, Amiral J, Guinet C, et al. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost 2010; 104: 1078-1079.
26. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
27. Bereznicki LR, Peterson GM. New Antithrombotics for Atrial Fibrillation. Cardiovasc Ther 2010; 28: 278-286.
28. Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010; 104: 49-60.